Editorial

1325 Tracking JAKs in spondyloarthritis: rationale and expectations
C Miceli-Richard, M Dougados

Recommendation

1327 Update of EULAR recommendations for the treatment of systemic sclerosis

Clinical and epidemiological research

1340 Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
D van der Heijde, A Dezellah, J C Wei, E Drescher, D Fleischaker, T Hendrikx, D Li, S Menon, K S Kenk

1348 Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, phase III randomised trial

1357 Long-term dietary quality and risk of developing rheumatoid arthritis in women
Y Hu, J A Sparks, S Matsuoka, K H Costenbader, F B Hu, E W Karlson, B Lu


1374 Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis
A Man, J K Correa, J Ziemek, R W Simms, D T Felson, R Laftisitis

1381 How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition

1389 Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study
P Carron, G Varkas, C Cypers, L Van Praet, D Elewaut, V Van den Bosch, on behalf of the CRESPA investigator group

1396 Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis
O Schier, C Toceski, R H Glazier, S Hogg-Johnson, E M Badley

Disclaimer
ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD is owned and published by the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement or approval of the products or services advertised, or guarantee editorial freedom to the Editor of ARD. Readers are advised to verify any information they choose to rely on.

Copyright: © 2017 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exter Prewmedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics. See http://publicationethics.org/
1405 Increased risk of rheumatoid arthritis among mothers with children who carry DRB1 risk-associated alleles
G I Cruz, X Shao, H Quach, K A Ho, K Sterba, J A Noble, N A Patapoutian, M P Busch, D J Trulz, W S W Wong, B D Solomon, J E Niederhuber, LA Criswell, L F Barcellos

1411 Dietary intake of fibre and risk of knee osteoarthritis in two US prospective cohorts
Z Dai, J Niu, Y Zhang, P Jacques, D T Felson

1420 Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus
C C Mok, L Y Ho, S M Tse, K Li Chan

1426 A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

1432 Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial
M Safy, J W G Jacobs, N D IJff, J W J Bijlsma, J M van Laar, M J H de Hair, On behalf of the Society for Rheumatology Research Utrecht (SRU)

1436 A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis
D Deng, P Zhang, Y Guo, T O Lim

1440 Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoinflammatory vasculitis

1449 Breach of autoreactive B cell tolerance by posttranslationally modified proteins

1458 Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjögren’s syndrome

1467 JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment
Y Zhang, R Liang, C W Chen, T Mallano, C Dees, A Distler, A Reich, C Bergmann, A Ramming, K Celze, M Mielenz, O Distler, G Shen, J H W Distler

1476 High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block
A R Lisney, F Szelinski, K Reiter, G R Burmester, T Rose, T Dörner

Electronic pages

Basic and translational research

1440 Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoinflammatory vasculitis

1449 Breach of autoreactive B cell tolerance by posttranslationally modified proteins

Correction

1480 Erratum: Eular/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Ann Rheum Dis 2017 76: e27-1480

Updated information and services can be found at: http://ard.bmj.com/content/76/8

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/